Lymphoma trial failure endangers Roche’s Gazyva growth plans as Rituxan biosims loom | FiercePharma
Roche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up. As a new-and-improved version of Roche’s best-selling >>>